---
document_datetime: 2025-12-02 06:25:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/udenyca.html
document_name: udenyca.html
version: success
processing_time: 0.1128482
conversion_datetime: 2025-12-23 23:25:46.396356
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Udenyca

[RSS](/en/individual-human-medicine.xml/65939)

##### Withdrawn

This medicine's authorisation has been withdrawn

pegfilgrastim Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Udenyca](#news-on)
- [Related content](#related-content-567)
- [More information on Udenyca](#more-information-on-udenyca-65054)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 4 February 2021, the European Commission withdrew the marketing authorisation for Udenyca (pegfilgrastim) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, ERA Consulting GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Udenyca was granted marketing authorisation in the EU on 21 September 2018 for treatment of neutropenia. The marketing authorisation was initially valid for a 5-year period. Udenyca is a biosimilar of Neulasta, which is authorised in the EU to treat neutropenia.

The European Public Assessment Report (EPAR) for Udenyca is updated to indicate that the marketing authorisation is no longer valid.

Udenyca : EPAR - Medicine overview

Reference Number: EMA/518623/2018

English (EN) (630.11 KB - PDF)

**First published:** 23/10/2018

[View](/en/documents/overview/udenyca-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-485)

български (BG) (681.39 KB - PDF)

**First published:**

23/10/2018

[View](/bg/documents/overview/udenyca-epar-medicine-overview_bg.pdf)

español (ES) (630.72 KB - PDF)

**First published:**

23/10/2018

[View](/es/documents/overview/udenyca-epar-medicine-overview_es.pdf)

čeština (CS) (669.03 KB - PDF)

**First published:**

23/10/2018

[View](/cs/documents/overview/udenyca-epar-medicine-overview_cs.pdf)

dansk (DA) (629.28 KB - PDF)

**First published:**

23/10/2018

[View](/da/documents/overview/udenyca-epar-medicine-overview_da.pdf)

Deutsch (DE) (631.57 KB - PDF)

**First published:**

23/10/2018

[View](/de/documents/overview/udenyca-epar-medicine-overview_de.pdf)

eesti keel (ET) (628.46 KB - PDF)

**First published:**

23/10/2018

[View](/et/documents/overview/udenyca-epar-medicine-overview_et.pdf)

ελληνικά (EL) (689.64 KB - PDF)

**First published:**

23/10/2018

[View](/el/documents/overview/udenyca-epar-medicine-overview_el.pdf)

français (FR) (631.48 KB - PDF)

**First published:**

23/10/2018

[View](/fr/documents/overview/udenyca-epar-medicine-overview_fr.pdf)

hrvatski (HR) (648 KB - PDF)

**First published:**

23/10/2018

[View](/hr/documents/overview/udenyca-epar-medicine-overview_hr.pdf)

italiano (IT) (628.96 KB - PDF)

**First published:**

23/10/2018

[View](/it/documents/overview/udenyca-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (666.83 KB - PDF)

**First published:**

23/10/2018

[View](/lv/documents/overview/udenyca-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (651.48 KB - PDF)

**First published:**

23/10/2018

[View](/lt/documents/overview/udenyca-epar-medicine-overview_lt.pdf)

magyar (HU) (666.36 KB - PDF)

**First published:**

23/10/2018

[View](/hu/documents/overview/udenyca-epar-medicine-overview_hu.pdf)

Malti (MT) (670.09 KB - PDF)

**First published:**

23/10/2018

[View](/mt/documents/overview/udenyca-epar-medicine-overview_mt.pdf)

Nederlands (NL) (630.67 KB - PDF)

**First published:**

23/10/2018

[View](/nl/documents/overview/udenyca-epar-medicine-overview_nl.pdf)

polski (PL) (671.65 KB - PDF)

**First published:**

23/10/2018

[View](/pl/documents/overview/udenyca-epar-medicine-overview_pl.pdf)

português (PT) (630.99 KB - PDF)

**First published:**

23/10/2018

[View](/pt/documents/overview/udenyca-epar-medicine-overview_pt.pdf)

română (RO) (649.77 KB - PDF)

**First published:**

23/10/2018

[View](/ro/documents/overview/udenyca-epar-medicine-overview_ro.pdf)

slovenčina (SK) (668.04 KB - PDF)

**First published:**

23/10/2018

[View](/sk/documents/overview/udenyca-epar-medicine-overview_sk.pdf)

slovenščina (SL) (662.99 KB - PDF)

**First published:**

23/10/2018

[View](/sl/documents/overview/udenyca-epar-medicine-overview_sl.pdf)

Suomi (FI) (628.69 KB - PDF)

**First published:**

23/10/2018

[View](/fi/documents/overview/udenyca-epar-medicine-overview_fi.pdf)

svenska (SV) (665.92 KB - PDF)

**First published:**

23/10/2018

[View](/sv/documents/overview/udenyca-epar-medicine-overview_sv.pdf)

Udenyca : EPAR - Risk-management-plan summary

English (EN) (659.71 KB - PDF)

**First published:** 29/10/2018

[View](/en/documents/rmp-summary/udenyca-epar-risk-management-plan-summary_en.pdf)

## Product information

Udenyca : EPAR - Product information

English (EN) (1.1 MB - PDF)

**First published:** 23/10/2018

**Last updated:** 29/11/2019

[View](/en/documents/product-information/udenyca-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-391)

български (BG) (1.33 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/bg/documents/product-information/udenyca-epar-product-information_bg.pdf)

español (ES) (1.22 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/es/documents/product-information/udenyca-epar-product-information_es.pdf)

čeština (CS) (1.26 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/cs/documents/product-information/udenyca-epar-product-information_cs.pdf)

dansk (DA) (1.21 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/da/documents/product-information/udenyca-epar-product-information_da.pdf)

Deutsch (DE) (1.2 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/de/documents/product-information/udenyca-epar-product-information_de.pdf)

eesti keel (ET) (1.2 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/et/documents/product-information/udenyca-epar-product-information_et.pdf)

ελληνικά (EL) (1.36 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/el/documents/product-information/udenyca-epar-product-information_el.pdf)

français (FR) (1.22 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/fr/documents/product-information/udenyca-epar-product-information_fr.pdf)

hrvatski (HR) (1.21 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/hr/documents/product-information/udenyca-epar-product-information_hr.pdf)

íslenska (IS) (1.18 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/is/documents/product-information/udenyca-epar-product-information_is.pdf)

italiano (IT) (1.17 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/it/documents/product-information/udenyca-epar-product-information_it.pdf)

latviešu valoda (LV) (1.26 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/lv/documents/product-information/udenyca-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.26 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/lt/documents/product-information/udenyca-epar-product-information_lt.pdf)

magyar (HU) (1.39 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/hu/documents/product-information/udenyca-epar-product-information_hu.pdf)

Malti (MT) (1.36 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/mt/documents/product-information/udenyca-epar-product-information_mt.pdf)

Nederlands (NL) (1.13 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/nl/documents/product-information/udenyca-epar-product-information_nl.pdf)

norsk (NO) (1.15 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/no/documents/product-information/udenyca-epar-product-information_no.pdf)

polski (PL) (1.37 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/pl/documents/product-information/udenyca-epar-product-information_pl.pdf)

português (PT) (1.25 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/pt/documents/product-information/udenyca-epar-product-information_pt.pdf)

română (RO) (1.27 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/ro/documents/product-information/udenyca-epar-product-information_ro.pdf)

slovenčina (SK) (1.29 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/sk/documents/product-information/udenyca-epar-product-information_sk.pdf)

slovenščina (SL) (1.27 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/sl/documents/product-information/udenyca-epar-product-information_sl.pdf)

Suomi (FI) (1.25 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/fi/documents/product-information/udenyca-epar-product-information_fi.pdf)

svenska (SV) (1.16 MB - PDF)

**First published:**

23/10/2018

**Last updated:**

29/11/2019

[View](/sv/documents/product-information/udenyca-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00002326/201901 22/11/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Udenyca : EPAR - All Authorised presentations

English (EN) (571.47 KB - PDF)

**First published:** 23/10/2018

[View](/en/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-794)

български (BG) (617.16 KB - PDF)

**First published:**

23/10/2018

[View](/bg/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_bg.pdf)

español (ES) (574.9 KB - PDF)

**First published:**

23/10/2018

[View](/es/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_es.pdf)

čeština (CS) (607.36 KB - PDF)

**First published:**

23/10/2018

[View](/cs/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (575.82 KB - PDF)

**First published:**

23/10/2018

[View](/da/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (575.13 KB - PDF)

**First published:**

23/10/2018

[View](/de/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (574.97 KB - PDF)

**First published:**

23/10/2018

[View](/et/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (615.45 KB - PDF)

**First published:**

23/10/2018

[View](/el/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_el.pdf)

français (FR) (574.94 KB - PDF)

**First published:**

23/10/2018

[View](/fr/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (581.43 KB - PDF)

**First published:**

23/10/2018

[View](/hr/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (572.29 KB - PDF)

**First published:**

23/10/2018

[View](/is/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_is.pdf)

italiano (IT) (574.99 KB - PDF)

**First published:**

23/10/2018

[View](/it/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (610.92 KB - PDF)

**First published:**

23/10/2018

[View](/lv/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (583.27 KB - PDF)

**First published:**

23/10/2018

[View](/lt/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (605.81 KB - PDF)

**First published:**

23/10/2018

[View](/hu/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (609.88 KB - PDF)

**First published:**

23/10/2018

[View](/mt/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (575.14 KB - PDF)

**First published:**

23/10/2018

[View](/nl/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (572.3 KB - PDF)

**First published:**

23/10/2018

[View](/no/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_no.pdf)

polski (PL) (608.4 KB - PDF)

**First published:**

23/10/2018

[View](/pl/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_pl.pdf)

português (PT) (574.96 KB - PDF)

**First published:**

23/10/2018

[View](/pt/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_pt.pdf)

română (RO) (592.43 KB - PDF)

**First published:**

23/10/2018

[View](/ro/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (607.22 KB - PDF)

**First published:**

23/10/2018

[View](/sk/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (597.97 KB - PDF)

**First published:**

23/10/2018

[View](/sl/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (574.78 KB - PDF)

**First published:**

23/10/2018

[View](/fi/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (575.02 KB - PDF)

**First published:**

23/10/2018

[View](/sv/documents/all-authorised-presentations/udenyca-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Udenyca Active substance pegfilgrastim International non-proprietary name (INN) or common name pegfilgrastim Anatomical therapeutic chemical (ATC) code L03AA13

### Pharmacotherapeutic group

- Immunostimulants
- Colony stimulating factors

### Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## Authorisation details

EMA product number EMEA/H/C/004413

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

ERA Consulting GmbH

Lange Strasse 70

Opinion adopted 25/07/2018 Marketing authorisation issued 21/09/2018 Withdrawal of marketing authorisation 04/02/2021 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Udenyca : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (679.48 KB - PDF)

**First published:** 30/10/2019

**Last updated:** 29/11/2019

[View](/en/documents/procedural-steps-after/udenyca-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Udenyca-H-C-4413-PSUSA-00002326-201901 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/562284/2019

English (EN) (669.29 KB - PDF)

**First published:** 29/11/2019

[View](/en/documents/scientific-conclusion/udenyca-h-c-4413-psusa-00002326-201901-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Udenyca : EPAR - Public assessment report

Adopted

Reference Number: EMA/552721/2018

English (EN) (3.99 MB - PDF)

**First published:** 23/10/2018

[View](/en/documents/assessment-report/udenyca-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Udenyca

Adopted

Reference Number: EMA/490650/2018

English (EN) (624.38 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-udenyca_en.pdf)

#### News on Udenyca

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### Related content

- [Biosimilar medicines](/en/human-regulatory-overview/biosimilar-medicines-overview)

#### More information on Udenyca

Public statement on Udenyca: Withdrawal of the marketing authorisation in the European Union

Reference Number: EMA/561886/2020

English (EN) (128.49 KB - PDF)

**First published:** 15/02/2021

[View](/en/documents/public-statement/public-statement-udenyca-withdrawal-marketing-authorisation-european-union_en.pdf)

**This page was last updated on** 15/02/2021

## Share this page

[Back to top](#main-content)